✦ LIBER ✦

A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From the ENDEAVOR IV Trial

✍ Scribed by Martin B. Leon; Laura Mauri; Jeffrey J. Popma; Donald E. Cutlip; Eugenia Nikolsky; Charles O'Shaughnessy; Paul A. Overlie; Brent T. McLaurin; Stuart L. Solomon; John S. Douglas Jr; Michael W. Ball; Ronald P. Caputo; Ash Jain; Thaddeus R. Tolleson; Bernard M. Reen III; Ajay J. Kirtane; Peter J. Fitzgerald; Kweli Thompson; David E. Kandzari

Book ID: 119268661
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 923 KB
Volume: 55
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2009.08.067

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A RANDOMIZED COMPARISON OF THE ENDEAVOR

A RANDOMIZED COMPARISON OF THE ENDEAVOR DRUG (ABT-578) ELUTING STENT VERSUS TAXUS PACLITAXEL-ELUTING STENT IN DIABETIC PATIENTS: THREE-YEAR OUTCOMES FROM ENDEAVOR IV

✍ Kirtane, Ajay; Patel, Rikesh; O'Shaunessy, Charles; McLaurin, Brent; Kandzari, D 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 101 KB

FIVE YEAR CLINICAL RESULTS FROM ENDEAVOR

FIVE YEAR CLINICAL RESULTS FROM ENDEAVOR III: A RANDOMIZED COMPARISON OF THE ZOTAROLIMUS-ELUTING VERSUS SIROLIMUS-ELUTING STENTS IN DE NOVO NATIVE CORONARY LESIONS

✍ Kandzari, David E.; Mauri, Laura; Popma, Jeffrey; Turco, Mark A.; O'Shaunessy, C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB

TCT-404: Late Safety and Efficacy of a Z

TCT-404: Late Safety and Efficacy of a Zotarolimus-Eluting Stent Compared with a Paclitaxel-Eluting Stent in Patients with De Novo Coronary Lesions: Three-Year Follow-up from the ENDEAVOR IV Trial

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 228 KB

STENT THROMBOSIS FOLLOWING IMPLANTATION

STENT THROMBOSIS FOLLOWING IMPLANTATION OF ENDEAVOR ZOTAROLIMUS-ELUTING STENTS IN PATIENTS WITH COMPLEX CORONARY LESIONS – INSIGHTS FROM THE LARGE, PROSPECTIVE, RANDOMIZED, MULTICENTER OPTIMIZE TRIAL

✍ Costa, Ricardo A.; Abizaid, Alexandre; Bhatt, Deepak; Paula, Joao E. Tinoco de; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 182 KB